 LA JOLLA, Calif., Nov. 10, 2020 GLOBE NEWSWIRE -- Equillium, Inc. Nasdaq: EQ, a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that Bruce Steel, Equilliums chief executive officer and Krishna Polu, M.D., Equilliums chief medical officer, will present at two upcoming investor conferences in November 2020. 